Pazopanib

Pazopanib Reactions 1704, p296 - 2 Jun 2018 Appetite loss and changes in hair colour: case report A 32-year-old woman developed appetite loss and changes in hair colour during treatment with pazopanib for ovarian sertoli cell tumour. The gravida 1 woman had Marfan syndrome. She was diagnosed with high grade ovarian sertoli cell tumour. She underwent bilateral salpingo-oophorectomy. She had received treatment with various other chemotherapy regimen, and was disease free for 5 months. However, she represented with complaints of a dark-coloured umbilicus, abnormal genital bleeding and upper abdominal pain which required treatment with unspecified NSAIDs. She was found to have tumour recurrence with metastases of ovarian sertoli cell tumour in the endometrial cavity. She was started on treatment with oral pazopanib 800mg. An improvement in her condition was noted in one month of pazopanib treatment. However, she developed mild appetite loss and changes in hair colour as side effects of pazopanib treatment. Three months following the initiation of pazopanib, she had stable disease. The woman’s treatment with pazopanib was continued for further 2 months and was eventually discontinued due to oozing bleeding from the umbilical tumour. She was given supportive care for 3 months. Subsequently, she died due to underlying disease [time to reactions onset and outcomes not stated]. Author comment: "The side effects of pazopanib were mild appetite loss and changes in hair color." Inoue K, et al. Pazopanib treatment of a platinum-resistant recurrence of a high- grade Sertoli cell tumor and assessment of the treatment response by FDG-PET/ CT: A case report. Gynecologic Oncology Reports 24: 54-56, May 2018. Available from: URL: http://doi.org/10.1016/j.gore.2018.03.002 - Japan 803323233 0114-9954/18/1704-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved Reactions 2 Jun 2018 No. 1704 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals

Pazopanib

Reactions Weekly , Volume 1704 (1) – Jun 2, 2018
Free
1 page

Loading next page...
1 Page
 
/lp/springer_journal/pazopanib-0pyzYNUMWk
Publisher
Springer Journals
Copyright
Copyright © 2018 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
ISSN
0114-9954
eISSN
1179-2051
D.O.I.
10.1007/s40278-018-46939-3
Publisher site
See Article on Publisher Site

Abstract

Reactions 1704, p296 - 2 Jun 2018 Appetite loss and changes in hair colour: case report A 32-year-old woman developed appetite loss and changes in hair colour during treatment with pazopanib for ovarian sertoli cell tumour. The gravida 1 woman had Marfan syndrome. She was diagnosed with high grade ovarian sertoli cell tumour. She underwent bilateral salpingo-oophorectomy. She had received treatment with various other chemotherapy regimen, and was disease free for 5 months. However, she represented with complaints of a dark-coloured umbilicus, abnormal genital bleeding and upper abdominal pain which required treatment with unspecified NSAIDs. She was found to have tumour recurrence with metastases of ovarian sertoli cell tumour in the endometrial cavity. She was started on treatment with oral pazopanib 800mg. An improvement in her condition was noted in one month of pazopanib treatment. However, she developed mild appetite loss and changes in hair colour as side effects of pazopanib treatment. Three months following the initiation of pazopanib, she had stable disease. The woman’s treatment with pazopanib was continued for further 2 months and was eventually discontinued due to oozing bleeding from the umbilical tumour. She was given supportive care for 3 months. Subsequently, she died due to underlying disease [time to reactions onset and outcomes not stated]. Author comment: "The side effects of pazopanib were mild appetite loss and changes in hair color." Inoue K, et al. Pazopanib treatment of a platinum-resistant recurrence of a high- grade Sertoli cell tumor and assessment of the treatment response by FDG-PET/ CT: A case report. Gynecologic Oncology Reports 24: 54-56, May 2018. Available from: URL: http://doi.org/10.1016/j.gore.2018.03.002 - Japan 803323233 0114-9954/18/1704-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved Reactions 2 Jun 2018 No. 1704

Journal

Reactions WeeklySpringer Journals

Published: Jun 2, 2018

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off